drugset / Trial / NCT07605962
Phase 1/2 Study of UI-102 in Selected Advanced Cancers
Non-randomizedSequentialOpen-labelTreatment
Summary
This phase 1/2 first-in-human study is designed to assess the safety and efficacy of UI-102, a TLR7/8 agonist encapsulated in a Cholesteryl Pullulan Nanoparticle.
Timeline
- Start
- 2026-05-20
- Primary completion
- 2030-03-31
- Completion
- 2031-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | UI-102 | Unknown | — | Intravenous |